Funding for this research was provided by:
Ministero della Salute (GR-2011-02351534, Progetto Ricerca Corrente 2018-20)
Associazione Italiana per la Ricerca sul Cancro (IG-22027)
Received: 22 November 2021
Accepted: 17 March 2022
First Online: 12 April 2022
: Patients with a confirmed diagnosis of glioblastoma multiforme were enrolled in this study at IRCCS National Neurologic Institute “C. Besta” under the Ethical committee approvals number Prot.61. All the subjects agreed to participate according to the ethical guidelines of the 2013 Declaration of Helsinki and signed an informed consent for samples and anonymized information to be used. All the experimental procedures for the in vivo mice studies have been approved by the Ministry of Health (prog. N°7/2010 and 7/2013).
: All authors have seen and approved the manuscript and consent publication.
: The authors declare no competing interests. AL Vescovi has ownership interest in Hyperstem SA.